WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H581079
CAS#: 108895-49-4
Description: 5-Et-ddU, Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells. 3'-azido-2',3'-dideoxyuridine (5a), 3'-azido-5-ethyl-2',3'-dideoxyuridine (5c), and 3'-azido-2',3'-dideoxycytidine (7a) and its 5-methyl analogue (7b) were identified as potent and selective anti-HIV-1 agent in primary human lymphocytes.
Hodoodo Cat#: H581079
Name: 5-Et-ddU
CAS#: 108895-49-4
Chemical Formula: C11H16N2O4
Exact Mass: 240.11
Molecular Weight: 240.260
Elemental Analysis: C, 54.99; H, 6.71; N, 11.66; O, 26.64
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: 5-Et-ddU; 5-Ethyl-2',3'-dideoxyuridine; D2EtU; ddEtUrd;
IUPAC/Chemical Name: 2,4(1H,3H)-Pyrimidinedione, 5-ethyl-1-((2R,5S)-tetrahydro-5-(hydroxymethyl)-2-furanyl)-
InChi Key: MCKZMXMWYDOXBL-DTWKUNHWSA-N
InChi Code: InChI=1S/C11H16N2O4/c1-2-7-5-13(11(16)12-10(7)15)9-4-3-8(6-14)17-9/h5,8-9,14H,2-4,6H2,1H3,(H,12,15,16)/t8-,9+/m0/s1
SMILES Code: O=C1NC(C(CC)=CN1[C@@H]2O[C@H](CO)CC2)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 240.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Srivastav NC, Shakya N, Bhavanam S, Agrawal A, Tse C, Desroches N, Kunimoto DY, Kumar R. Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs. Bioorg Med Chem Lett. 2012 Jan 15;22(2):1091-4. doi: 10.1016/j.bmcl.2011.11.114. Epub 2011 Dec 4. PubMed PMID: 22178557.
2: Chu CK, Schinazi RF, Ahn MK, Ullas GV, Gu ZP. Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells. J Med Chem. 1989 Mar;32(3):612-7. PubMed PMID: 2918508.
3: Chu CK, Schinazi RF, Arnold BH, Cannon DL, Doboszewski B, Bhadti VB, Gu ZP. Comparative activity of 2',3'-saturated and unsaturated pyrimidine and purine nucleosides against human immunodeficiency virus type 1 in peripheral blood mononuclear cells. Biochem Pharmacol. 1988 Oct 1;37(19):3543-8. PubMed PMID: 3178868.
4: Balzarini J, Baba M, Pauwels R, Herdewijn P, De Clerq E. Anti-retrovirus activity of 3'-fluoro- and 3'-azido-substituted pyrimidine 2',3'-dideoxynucleoside analogues. Biochem Pharmacol. 1988 Jul 15;37(14):2847-56. PubMed PMID: 2840080.